Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
Department of Gynecologic Oncology, MD Anderson Cancer Center (MDACC), Houston, TX, USA.
Gynecol Oncol. 2014 Sep;134(3):455-61. doi: 10.1016/j.ygyno.2014.07.002. Epub 2014 Jul 11.
To assess the ability of preoperative computed tomography (CT) scan of the abdomen/pelvis and serum CA-125 to predict suboptimal (>1cm residual disease) primary cytoreduction in advanced ovarian, fallopian tube, and peritoneal cancer.
This was a prospective, non-randomized, multicenter trial of patients who underwent primary cytoreduction for stage III-IV ovarian, fallopian tube, and peritoneal cancer. A CT scan of the abdomen/pelvis and serum CA-125 were obtained within 35 and 14 days before surgery, respectively. Four clinical and 20 radiologic criteria were assessed.
From 7/2001 to 12/2012, 669 patients were enrolled; 350 met eligibility criteria. The optimal debulking rate was 75%. On multivariate analysis, three clinical and six radiologic criteria were significantly associated with suboptimal debulking: age ≥ 60 years (p=0.01); CA-125 ≥ 500 U/mL (p<0.001); ASA 3-4 (p<0.001); suprarenal retroperitoneal lymph nodes >1cm (p<0.001); diffuse small bowel adhesions/thickening (p<0.001); and lesions >1cm in the small bowel mesentery (p=0.03), root of the superior mesenteric artery (p=0.003), perisplenic area (p<0.001), and lesser sac (p<0.001). A 'predictive value score' was assigned for each criterion, and the suboptimal debulking rates of patients who had a total score of 0, 1-2, 3-4, 5-6, 7-8, and ≥ 9 were 5%, 10%, 17%, 34%, 52%, and 74%, respectively. A prognostic model combining these nine factors had a predictive accuracy of 0.758.
We identified nine criteria associated with suboptimal cytoreduction, and developed a predictive model in which the suboptimal rate was directly proportional to a predictive value score. These results may be helpful in pretreatment patient assessment.
评估术前腹部/骨盆计算机断层扫描(CT)和血清 CA-125 预测晚期卵巢、输卵管和腹膜癌初始细胞减灭术不充分(残留病灶>1cm)的能力。
这是一项针对接受 III-IV 期卵巢、输卵管和腹膜癌初始细胞减灭术的患者的前瞻性、非随机、多中心试验。在手术前 35 天和 14 天内分别获得腹部/骨盆 CT 扫描和血清 CA-125。评估了 4 项临床和 20 项影像学标准。
从 2001 年 7 月至 2012 年 12 月,共纳入 669 例患者;其中 350 例符合入选标准。最佳减瘤率为 75%。多变量分析显示,3 项临床和 6 项影像学标准与不充分减瘤显著相关:年龄≥60 岁(p=0.01);CA-125≥500U/mL(p<0.001);ASA 3-4 级(p<0.001);肾上腺后腹膜淋巴结>1cm(p<0.001);弥漫性小肠粘连/增厚(p<0.001);以及小肠系膜病变>1cm(p=0.03)、肠系膜上动脉根部(p=0.003)、脾周区域(p<0.001)和小网膜囊(p<0.001)。为每个标准分配了“预测值评分”,总分为 0、1-2、3-4、5-6、7-8 和≥9 的患者的不充分减瘤率分别为 5%、10%、17%、34%、52%和 74%。结合这 9 个因素的预后模型预测准确率为 0.758。
我们确定了与不充分细胞减灭相关的 9 个标准,并建立了一个预测模型,其中不充分率与预测值评分成正比。这些结果可能有助于术前患者评估。